A pilot study of camrelizumab with docetaxel and cisplatin for the first line treatment in recurrent/metastatic oral squamous cell carcinoma

Pembrolizumab with cisplatin and 5‐fluorouracil showed survival benefit but relatively high occurrence of treatment‐related adverse events (TRAEs) for recurrent/metastatic oral squamous cell carcinoma (R/M OSCC). A more tolerable regime is needed. This trial enrolled 20 R/M OSCC patients with previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Houyu, Wei, Dongliang, Wu, Yunteng, Liu, Yang, Ding, Qi, Rui, Mengyu, Fan, Zongyu, Yao, Yanli, Hu, Jingzhou, Ren, Guoxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363852/
https://www.ncbi.nlm.nih.gov/pubmed/37492783
http://dx.doi.org/10.1002/mco2.312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363852/
https://www.ncbi.nlm.nih.gov/pubmed/37492783
http://dx.doi.org/10.1002/mco2.312

Ejemplares similares